参附注射液联合阿托伐他汀治疗慢性阻塞性肺疾病急性加重期的临床观察

发布时间：2018-01-03 09:05

本文关键词：参附注射液联合阿托伐他汀治疗慢性阻塞性肺疾病急性加重期的临床观察　出处：《中国药房》2015年09期 　论文类型：期刊论文

【摘要】：目的:观察参附注射液联合阿托伐他汀治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效、安全性及其对血清炎症因子、肺功能的影响。方法:将70例AECOPD患者随机均分为两组,对照组患者给予支气管扩张、抗感染等常规治疗;观察组患者在此基础上给予参附注射液20 ml加入5%葡萄糖注射液或0.9%氯化钠注射液250 ml中静脉滴注,qd,并给予阿托伐他汀20mg口服,qd。于治疗14 d后比较两组患者肺功能、血清炎症因子水平及临床疗效和不良反应发生情况。结果:两组患者治疗后1 s用力呼气容积(FEV1)占预计值百分比(FEV1%)、FEV1与用力肺活量的比值(FEV1/FVC)均较治疗前显著提高,且观察组显著高于对照组,差异均有统计学意义(P0.05);血清C反应蛋白(CRP)、白介素8(IL-8)水平均较治疗前显著降低,且观察组显著低于对照组,差异均有统计学意义(P0.05)。观察组患者总有效率显著高于对照组,两组比较差异有统计学意义(P0.05)。两组患者均未见相关不良反应发生。结论:参附注射液联合阿托伐他汀治疗AECOPD可有效抑制炎症反应,改善肺功能,提高临床疗效,且具有较好的安全性。
[Abstract]:Objective: to observe the clinical efficacy, safety and serum inflammatory factors of Shenfu injection combined with Atto vastatin in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods: 70 patients with AECOPD were randomly divided into two groups: the control group received bronchiectasis, anti-infection and other routine treatment. On this basis, the patients in the observation group were given 20 ml Shenfu injection plus 5% glucose injection or 250ml sodium chloride injection intravenous drip QD. After 14 days of treatment, the pulmonary function of the two groups was compared. Results: forced expiratory volume (FEV1) and FEV1 / FEV1 were the percentage of predicted value in the two groups after treatment (FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1 / FEV1). The ratio of FEV1 to forced vital capacity (RVV) and FEV1 / FVCwere significantly higher in the observation group than in the control group (P 0.05). The levels of serum C-reactive protein (CRP) and interleukin-8 (IL-8) were significantly lower in the observation group than before treatment, and were significantly lower in the observation group than in the control group. The difference was statistically significant (P 0.05). The total effective rate in the observation group was significantly higher than that in the control group. The difference between the two groups was statistically significant (P 0.05). There were no related adverse reactions in the two groups. Conclusion: Shenfu injection combined with Atto vastatin can effectively inhibit the inflammatory response of AECOPD. Improve lung function, improve clinical efficacy, and have better safety.
【作者单位】：惠州市中医医院;
【基金】：惠州市科技计划项目(No.2014Y077)
【分类号】：R563.9
【正文快照】： 慢性阻塞性肺疾病(Chronic obstructive pulmonary dis-ease,COPD)是最常见的慢性呼吸系统疾病之一,在我国40岁以上人群中COPD患病率高达8.2%[1],已成为严重的公共健康问题。COPD病因尚未完全明确,目前认为其中心环节为气道、肺实质和肺血管的慢性炎症性反应,发病与空气污染、

【相似文献】